Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Cytokinetics (CYTK) over the last 6 years, with Sep 2025 value amounting to $2.9 million.

  • Cytokinetics' Gains from Investment Securities was N/A to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 11.55% down from last year.
  • Cytokinetics' Gains from Investment Securities amounted to $2.9 million in Q3 2025, which was down 16.42% from $3.5 million recorded in Q1 2025.
  • In the past 5 years, Cytokinetics' Gains from Investment Securities registered a high of $77.9 million during Q1 2021, and its lowest value of -$2.8 million during Q4 2021.
  • Over the past 3 years, Cytokinetics' median Gains from Investment Securities value was $3.5 million (recorded in 2025), while the average stood at $7.3 million.
  • The largest annual percentage gain for Cytokinetics' Gains from Investment Securities in the last 5 years was 6,942.22% (2021), contrasted with its biggest fall of 344.82% (2021).
  • Cytokinetics' Gains from Investment Securities (Quarterly) stood at -$2.8 million in 2021, then soared by 146.29% to $1.3 million in 2022, then climbed by 9.53% to $10.5 million in 2023, then surged by 75.42% to $1.2 million in 2024, then crashed by 81.02% to $2.9 million in 2025.
  • Its Gains from Investment Securities stands at $2.9 million for Q3 2025, versus $3.5 million for Q1 2025 and $1.2 million for Q4 2024.